First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic…
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib BASEL, 11-7-2014 — /EuropaWire/…